Maat Pharma · EURONEXT:MAAT
Maat Pharma — Investor Presentation (May 2024)
30 slides from Maat Pharma's investor presentation, May 2024
Slide 1: Enhancing Survival through Microbiome Innovation
Enhancing Survival through Microbiome Innovation May 2024
Slide 2: Disclaimer
MaaT Pharma 02 Disclaimer This document has been prepared by MaaT Pharma (the "Company") The information contained in this document has not been subject to This document contains certain forward-looking statements. These and is for information and background purposes only. independent verification a
Slide 3: Late-Stage Clinical Biotech, Leading the Way in Microbiome Therapies in Oncology
MaaT Pharma 03 Late-Stage Clinical Biotech, Leading the Way in Microbiome Therapies in Oncology MaaT013 in Phase 3 in aGvHD Deep oncology pipeline Finance Revenues of MaaT013 in aGvHD Lead asset MaaT013 in Phase 3 Donor-derived and co-culture of 2.2m€ for 2023 from Early in aGvHD in Europe, expectin
Slide 4: Host–Microbiota Interactions are Critical for a Functional Immune System
MaaT Pharma 04 Host – Microbiota Interactions are Critical for a Functional Immune System A diversified microbiome contributes to the education 01 and modulation of our immune system throughout life Bacterial richness and mucus layer prevent colonization 02 by pathogens and improve gut barrier Cross
Slide 5: In Oncology, a Higher Gut Microbiome Diversity is Associated with Increased Survival
MaaT Pharma 05 In Oncology, a Higher Gut Microbiome Diversity is Associated with Increased Survival Liquid Tumors Solid Tumors Higher survival rate in patients Lower incidence and lower mortality Higher response rate to ICI* in patients receiving allo-HSCT*1 from aGvHD*2 with metastatic melanoma3 Ov
Slide 6: An Oncology Microbiome Platform Fueling a Deep Pipeline of Drug Candidates
MaaT Pharma 06 An Oncology Microbiome Platform Fueling a Deep Pipeline of Drug Candidates Driving near-term value Progressing next-generation Leading capabilities with the donor-derived MET-N platform co-cultured scalable MET-C platform in microbiome drug production MaaT013 MaaT034 MaaT033 MaaT03X ~
Slide 7: AI-driven Research Engine Powered by Metagenomics Enabling Candidate Selection
MaaT Pharma 07 AI-driven Research Engine Powered by Metagenomics Enabling Candidate Selection DATA Healthy Selected Native Therapeutics donors MET-N Leading Platform AI ENGINE Leading discovery and AI-driven platform DATA for Microbiome for selecting the best candidates and Patients Discovery proces
Slide 8: A Strong Pipeline With Multiple Near-Term Value Inflection Milestones
MaaT Pharma 08 A Strong Pipeline With Multiple Near-Term Value Inflection Milestones Platform Program Indication Preclinical Phase I Phase II Phase III Upcoming milestone ARES GI-ORR mid Q4 2024 MaaT013 EAP ongoing: 140 pts treated EBMT Data April 2024 MET-N PICASSO (IST) Results H2.24/ Q1.25 PHOEBU
Slide 9: Targeting Multiple Attractive Markets with Unmet Medical Need
MaaT Pharma 09 Targeting Multiple Attractive Markets with Unmet Medical Need ~1 to 5b€ 1 ~500m€ 1 3rd Line: ~200m€ 1 1L :10k patients2 2L : 5K patients2 11k patients2 3L : 3K patients2 500k patients2 ++k patients2 1PYS EU5, US; 2 Per year
Slide 10: Driving Near-Term Value with the Donor-Derived MET-N Platform
Driving Near-Term Value with the Donor- Derived MET-N Platform MET-N
Slide 11: Microbiome Restoration with MaaT013: A Maximum-Density Product for Fast Engraftment
MaaT Pharma MaaT013 11 Microbiome Restoration with MaaT013: A Maximum-Density Product for Fast Engraftment in Acute Situations Pooled microbiota: high-richness, high-diversity, full ecosystem 01 Characteristics Microbiome Therapy containing Butycore® Non immunosuppressive treatment 02 Administration
Slide 12: MaaT013, a Novel Agent to Treat aGvHD Restoring Immune Homeostasis and Gut Barrier
MaaT Pharma MaaT013 aGvHD 12 MaaT013, a Novel Agent to Treat aGvHD Acting by Restoring Immune Homeostasis and Gut Barrier Integrity MaaT013 Restoration of barrier integrity Production of immunoregulatory metabolites • SCFA ( Butyrate, Proprionate) • Immunoregulation (IL-10…) Restoration of microbial
Slide 13: Unmet Medical Need: aGvHD Resistant to Steroids and Ruxolitinib
MaaT Pharma MaaT013 aGvHD 13 Unmet Medical Need: Acute Graft-versus-Host Disease (aGvHD) Resistant to Steroids and Ruxolitinib (3rd line of treatment) Acute Graft-versus-Host Disease Treatment Paradigm c. 30% of patients have no effective treatment option aGvHD is a condition where Corticosteroids a
Slide 14: ARES, a Pivotal Phase 3 Trial to Treat aGvHD in 3rd Line
MaaT Pharma MaaT013 aGvHD 14 ARES, a Pivotal Phase 3 Trial to Treat aGvHD in 3rd Line Showing “high efficacy and low toxicity” as Concluded by the DSMB Treatment Period D1, 5, 10 Primary follow-up Long-term follow-up Patients EOT Screening with SR-GI-aGvHD (D-14 to D-1) MaaT013 administration 4th do
Slide 15: The EAP Data Confirms Significant Improvement of Survival with High Level of Response
MaaT Pharma MaaT013 aGvHD 15 The EAP Data Confirms Significant Improvement of Survival with High Level of Response Global EAP populations ARES-like populations from EAP GI-ORR Overall Survival Rate GI-ORR Overall Survival Rate Patients (%) Survival (%) Patients (%) Survival (%) 100 100 60 60 40 50 4
Slide 16: Proof-of-Concept with MaaT013 in Combination with ICI
MaaT Pharma MaaT013 16 Proof-of-Concept with MaaT013 in Combination with ICI In Metastatic Melanoma Serves as PoC for MaaT034 in combination with ICI MET-N
Slide 17: MaaT013 Evaluated in Phase 2 Randomized Clinical Trial in Melanoma
MaaT Pharma POC - MaaT013 IO 17 MaaT013 Evaluated in Phase 2 Randomized Clinical Trial in Melanoma MaaT013 Relative Low High abundance Faecalibacterium Bifidobacterium Recruitment completed Ph. 2a PICASSO High trial High Medium Investigator led trial (Assistance Publique - Hôpitaux de Paris – sponso
Slide 18: MaaT033 - The Oral Ecosystem Microbiome Capsule for Adjunctive and Maintenance Therapy
MaaT Pharma MaaT033 18 Ensuring Optimal Microbiota Function: MaaT033 - The Oral Ecosystem Microbiome Capsule for Adjunctive and Maintenance Therapy Pooled microbiota : high-richness, high-diversity, full ecosystem, 01 Characteristics Microbiome Ecosystem Therapy containing Butycore® Non immunosuppre
Slide 19: MaaT033 to Ensure Optimal Gut Microbiota to Improve Survival in Patients Receiving Allogeneic HSCT
MaaT Pharma MaaT033 allo-HSCT 19 MaaT033 to Ensure Optimal Gut Microbiota to Improve Survival in Patients Receiving Allogeneic HSCT Chemotherapy Antibiotics United States EU 5 Japan Allogenic Hematopoietic → Irradiation Stem Cell Transplantation → Immunosuppressors (allo-HSCT) c. 7,800 c. 9,600 c. 3
Slide 20: MaaT033: a Potential Adjunctive Treatment for Patients Receiving allo-HSCT
MaaT Pharma MaaT033 allo-HSCT 20 MaaT033: a Potential Adjunctive Treatment for Patients Receiving allo-HSCT → 387 patients in a randomized, double-blind, placebo-controlled → Primary endpoint efficacy of MaaT033 in improving overall survival international study at 12 months → 56 sites targeted globa
Slide 21: MaaT033 Aims to Slow Down Amyotrophic Lateral Sclerosis Progression
MaaT Pharma MaaT033 ALS 21 MaaT033 Aims to Slow Down Amyotrophic Lateral Sclerosis Progression Amyotrophic Lateral Sclerosis Study → Up to 15 patients in a pilot, open-label, Phase 1b study in France → Could affect up to 60,000 patients in US & EU by 2040 1 → Paralysis and death 3 to 5 years after d
Slide 22: Progressing the Next-Generation, Co-Cultured, Donor Independent MET-C Platform
Progressing the Next- Generation, Co-Cultured, Donor Independent MET-C Platform MET-C
Slide 23: MET-C Product Generation Driven by Proprietary Predictive AI and Eubiotic Score
MaaT Pharma MET-C 23 MET-C Product Generation is Driven by MaaT Pharma’s Proprietary Predictive AI, Eubiotic Score and in vitro and in vivo validation processes In silico In vitro In vivo Clinic Data Drug discovery Drug development Indication-specific Donor-independent drug candidates Clinical & hos
Slide 24: End-to-End In-house cGMP Manufacturing
End-to-End In-house cGMP Manufacturing All MET
Slide 25: Europe's Largest Specialized cGMP Manufacturing Facility for Microbiome Ecosystem Therapies
MaaT Pharma All MET 25 Europe’s Largest 01 Specialized cGMP Fully integrated Manufacturing and development Manufacturing platform for a streamlined product development, Facility for Microbiome scaleup and GMP process. Ecosystem Therapies 02 A dedicated 1,600m2 site (expandable) to support demands un
Slide 26: Key Takeaways
Key Takeaways
Slide 27: Multiple Near-Term Value Inflection Milestones
MaaT Pharma 27 Multiple Near-Term Value Inflection Milestones 2024 2025 Fina nce Revenues of MaaT013 in aGvHD of 2.2m€ for 2023 from Early MaaT013 (pooled enema) MaaT013 (pooled enema) Access Program GvHD | Final Results (OS) GvHD | EAP long term follow-up EBMT24 GvHD | ARES P3 GI-ORR mid Q4 24 Cash
Slide 28: A Robust Value Creation Strategy Driven by Leading Expertise in Microbiome-based Therapeutics
MaaT Pharma 28 A Robust Value Creation Strategy Driven by Leading Expertise in Microbiome-based Therapeutics MET-N MET-C MaaT03X MaaT034 MaaT033 MaaT013 Adressable Co-cultured caps. Co-cultured capsule Patients Pooled enema Pooled capsule Synthetic eubiotic microbiota Indication specific Creation Va
Slide 29: Corporate Social Responsibility
MaaT Pharma 29 Corporate Social Responsibility MaaT Pharma aims to become the source Patients are our priority. We are committed → Innovate and raise awareness to deliver of Microbiome excellence providing patients to our patients and to the protection of human better care, with safe and innovative
Slide 30: Thank you
Thank you invest@maat-pharma.com